Hepatitis B vaccination of 113 hemophiliacs: Lower antibody response in anti-LAV/HTLV-III-positive patients

A. R. Zanetti, P. M. Mannucci, E. Tanzi, G. A. Moroni, M. De Paschale, M. Morfini, V. Carnelli, M. C. Tirindelli, R. De Biasi, N. Ciavarella

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

One hundred thirteen adults and children with hemophilia or other congenital bleeding disorders were vaccinated against the hepatitis B virus. Each patient was given 3 subcutaneous injections of the vaccine at monthly intervals and then a 4th booster dose 14 months after the first. The vaccine was highly immunogenic, since 111 of 113 patients (98%) produced anti-HBs (10 mIU/ml or more). After the first 3 vaccine doses and after the booster dose, 10 anti-LAV/HTLV-III-positive hemophiliacs produced anti-HBs but had a lower average titer than anti-LAV/HTLV-III-negative hemophiliacs. Of the 23 patients treated with concentrates in the 15-month postvaccination period only, none acquired HBV infection. Of the 50 patients treated with concentrates also in the 6-month prevaccination period, one developed hepatitis B. In summary, the vaccine was highly immunogenic in both children and adults with hemophilia; anti-LAV/HTLV-III-positive patients responded to the vaccine, but the average anti-HBs response was lower; no case of hepatitis B occurred in patients treated with concentrates only in the postvaccination period.

Original languageEnglish
Pages (from-to)339-345
Number of pages7
JournalAmerican Journal of Hematology
Volume23
Issue number4
DOIs
Publication statusPublished - 1986

Fingerprint

Hepatitis B
Antibody Formation
Vaccination
HIV
Vaccines
Hemophilia A
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Subcutaneous Injections
Hepatitis B virus
Hemorrhage
Infection

ASJC Scopus subject areas

  • Hematology

Cite this

Hepatitis B vaccination of 113 hemophiliacs : Lower antibody response in anti-LAV/HTLV-III-positive patients. / Zanetti, A. R.; Mannucci, P. M.; Tanzi, E.; Moroni, G. A.; De Paschale, M.; Morfini, M.; Carnelli, V.; Tirindelli, M. C.; De Biasi, R.; Ciavarella, N.

In: American Journal of Hematology, Vol. 23, No. 4, 1986, p. 339-345.

Research output: Contribution to journalArticle

Zanetti, AR, Mannucci, PM, Tanzi, E, Moroni, GA, De Paschale, M, Morfini, M, Carnelli, V, Tirindelli, MC, De Biasi, R & Ciavarella, N 1986, 'Hepatitis B vaccination of 113 hemophiliacs: Lower antibody response in anti-LAV/HTLV-III-positive patients', American Journal of Hematology, vol. 23, no. 4, pp. 339-345. https://doi.org/10.1002/ajh.2830230406
Zanetti, A. R. ; Mannucci, P. M. ; Tanzi, E. ; Moroni, G. A. ; De Paschale, M. ; Morfini, M. ; Carnelli, V. ; Tirindelli, M. C. ; De Biasi, R. ; Ciavarella, N. / Hepatitis B vaccination of 113 hemophiliacs : Lower antibody response in anti-LAV/HTLV-III-positive patients. In: American Journal of Hematology. 1986 ; Vol. 23, No. 4. pp. 339-345.
@article{5b81e0f4be684f05b33185584dfaa7fd,
title = "Hepatitis B vaccination of 113 hemophiliacs: Lower antibody response in anti-LAV/HTLV-III-positive patients",
abstract = "One hundred thirteen adults and children with hemophilia or other congenital bleeding disorders were vaccinated against the hepatitis B virus. Each patient was given 3 subcutaneous injections of the vaccine at monthly intervals and then a 4th booster dose 14 months after the first. The vaccine was highly immunogenic, since 111 of 113 patients (98{\%}) produced anti-HBs (10 mIU/ml or more). After the first 3 vaccine doses and after the booster dose, 10 anti-LAV/HTLV-III-positive hemophiliacs produced anti-HBs but had a lower average titer than anti-LAV/HTLV-III-negative hemophiliacs. Of the 23 patients treated with concentrates in the 15-month postvaccination period only, none acquired HBV infection. Of the 50 patients treated with concentrates also in the 6-month prevaccination period, one developed hepatitis B. In summary, the vaccine was highly immunogenic in both children and adults with hemophilia; anti-LAV/HTLV-III-positive patients responded to the vaccine, but the average anti-HBs response was lower; no case of hepatitis B occurred in patients treated with concentrates only in the postvaccination period.",
author = "Zanetti, {A. R.} and Mannucci, {P. M.} and E. Tanzi and Moroni, {G. A.} and {De Paschale}, M. and M. Morfini and V. Carnelli and Tirindelli, {M. C.} and {De Biasi}, R. and N. Ciavarella",
year = "1986",
doi = "10.1002/ajh.2830230406",
language = "English",
volume = "23",
pages = "339--345",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Hepatitis B vaccination of 113 hemophiliacs

T2 - Lower antibody response in anti-LAV/HTLV-III-positive patients

AU - Zanetti, A. R.

AU - Mannucci, P. M.

AU - Tanzi, E.

AU - Moroni, G. A.

AU - De Paschale, M.

AU - Morfini, M.

AU - Carnelli, V.

AU - Tirindelli, M. C.

AU - De Biasi, R.

AU - Ciavarella, N.

PY - 1986

Y1 - 1986

N2 - One hundred thirteen adults and children with hemophilia or other congenital bleeding disorders were vaccinated against the hepatitis B virus. Each patient was given 3 subcutaneous injections of the vaccine at monthly intervals and then a 4th booster dose 14 months after the first. The vaccine was highly immunogenic, since 111 of 113 patients (98%) produced anti-HBs (10 mIU/ml or more). After the first 3 vaccine doses and after the booster dose, 10 anti-LAV/HTLV-III-positive hemophiliacs produced anti-HBs but had a lower average titer than anti-LAV/HTLV-III-negative hemophiliacs. Of the 23 patients treated with concentrates in the 15-month postvaccination period only, none acquired HBV infection. Of the 50 patients treated with concentrates also in the 6-month prevaccination period, one developed hepatitis B. In summary, the vaccine was highly immunogenic in both children and adults with hemophilia; anti-LAV/HTLV-III-positive patients responded to the vaccine, but the average anti-HBs response was lower; no case of hepatitis B occurred in patients treated with concentrates only in the postvaccination period.

AB - One hundred thirteen adults and children with hemophilia or other congenital bleeding disorders were vaccinated against the hepatitis B virus. Each patient was given 3 subcutaneous injections of the vaccine at monthly intervals and then a 4th booster dose 14 months after the first. The vaccine was highly immunogenic, since 111 of 113 patients (98%) produced anti-HBs (10 mIU/ml or more). After the first 3 vaccine doses and after the booster dose, 10 anti-LAV/HTLV-III-positive hemophiliacs produced anti-HBs but had a lower average titer than anti-LAV/HTLV-III-negative hemophiliacs. Of the 23 patients treated with concentrates in the 15-month postvaccination period only, none acquired HBV infection. Of the 50 patients treated with concentrates also in the 6-month prevaccination period, one developed hepatitis B. In summary, the vaccine was highly immunogenic in both children and adults with hemophilia; anti-LAV/HTLV-III-positive patients responded to the vaccine, but the average anti-HBs response was lower; no case of hepatitis B occurred in patients treated with concentrates only in the postvaccination period.

UR - http://www.scopus.com/inward/record.url?scp=0022968428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022968428&partnerID=8YFLogxK

U2 - 10.1002/ajh.2830230406

DO - 10.1002/ajh.2830230406

M3 - Article

C2 - 3098092

AN - SCOPUS:0022968428

VL - 23

SP - 339

EP - 345

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -